147 related articles for article (PubMed ID: 35485345)
1. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.
Lee JE; Lee SO; Heo J; Kim DW; Park MR; Son H; Kim D; Kim KH; Lee S; Lee SH
Antivir Ther; 2021; 26(1-2):34-42. PubMed ID: 35485345
[TBL] [Abstract][Full Text] [Related]
2. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.
Choi MJ; Kang M; Shin SY; Noh JY; Cheong HJ; Kim WJ; Jung J; Song JY
Int J Infect Dis; 2021 Jan; 102():275-281. PubMed ID: 33127507
[TBL] [Abstract][Full Text] [Related]
3. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.
Giacomelli A; Pagani G; Ridolfo AL; Oreni L; Conti F; Pezzati L; Bradanini L; Casalini G; Bassoli C; Morena V; Passerini S; Rizzardini G; Cogliati C; Ceriani E; Colombo R; Rusconi S; Gervasoni C; Cattaneo D; Antinori S; Galli M
J Med Virol; 2021 Mar; 93(3):1421-1427. PubMed ID: 32776534
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.
Karolyi M; Pawelka E; Mader T; Omid S; Kelani H; Ely S; Jilma B; Baumgartner S; Laferl H; Ott C; Traugott M; Turner M; Seitz T; Wenisch C; Zoufaly A
Wien Klin Wochenschr; 2021 Apr; 133(7-8):284-291. PubMed ID: 32776298
[TBL] [Abstract][Full Text] [Related]
5. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
[TBL] [Abstract][Full Text] [Related]
6. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
[TBL] [Abstract][Full Text] [Related]
7. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
Huang YQ; Tang SQ; Xu XL; Zeng YM; He XQ; Li Y; Harypursat V; Lu YQ; Wan Y; Zhang L; Sun QZ; Sun NN; Wang GX; Yang ZP; Chen YK
Front Pharmacol; 2020; 11():1071. PubMed ID: 32765274
[TBL] [Abstract][Full Text] [Related]
8. Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.
Mazaherpour H; Sofian M; Farahani E; Abdi A; Mazaherpour S; Bavand A; Ramezani A
Biomed Res Int; 2022; 2022():1522426. PubMed ID: 35013710
[TBL] [Abstract][Full Text] [Related]
9. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H
PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.
Luo P; Zheng JL; Liu Y; Qiu L; Liu XL; Xue HY; Liu D; Li J
Clin Med (Lond); 2021 Jan; 21(1):e80-e83. PubMed ID: 33355217
[TBL] [Abstract][Full Text] [Related]
12. Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study.
Wong CKH; Low MCH; Kwok ACY; Lui AYC; Lau KTK; Au ICH; Xiong X; Chung MSH; Kwan MYW; Lau EHY; Cowling BJ
Paediatr Drugs; 2022 May; 24(3):269-280. PubMed ID: 35428969
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
Qu J; Li GH; Wang JJ; He GF; Huang JJ; Chen Y; Qu Q; Chen XY; Lu Q
Clin Exp Pharmacol Physiol; 2021 Feb; 48(2):203-210. PubMed ID: 33090501
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
[TBL] [Abstract][Full Text] [Related]
15. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
[TBL] [Abstract][Full Text] [Related]
16. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Kalantari S; Fard SR; Maleki D; Taher MT; Yassin Z; Alimohamadi Y; Minaeian S
J Med Virol; 2021 Dec; 93(12):6557-6565. PubMed ID: 34255369
[TBL] [Abstract][Full Text] [Related]
17. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
19. Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients.
Gao G; Wang A; Wang S; Qian F; Chen M; Yu F; Zhang J; Wang X; Ma X; Zhao T; Zhang F; Chen Z
J Acquir Immune Defic Syndr; 2020 Oct; 85(2):239-243. PubMed ID: 32740371
[TBL] [Abstract][Full Text] [Related]
20. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
